ネオモルフタンパク質インターフェースは,腫瘍におけるRASG12Dの共性阻害を触媒する
Caroline Weller1, G Leslie Burnett1, Lingyan Jiang1
1Revolution Medicines, Inc., Redwood City, CA, USA.
Science (New York, N.Y.)
|July 24, 2025
まとめ
研究者は,ユニークなタンパク質の相互作用を創造することによって,KRASG12Dがんを標的とした新しい共性阻害剤を開発しました. このアプローチは強力な薬剤の投与を可能にし,臨床前のがんモデルでは有望であることが示されています.
科学分野:
- 腫瘍学
- 分子生物学
- 薬物の発見
背景:
- 変異したRASタンパク質,特にKRASG12Dは,多数のヒトがんの主要な原動力である.
- KRASG12Dを共性阻害剤で標的化することは,反応性が低く,体内の類似分子の豊富さのために困難です.
研究 の 目的:
- KRASG12Dを共同でターゲットにするという課題を克服する.
- KRASG12D誘発がんに対する選択性と有効性を高める新しい抑制剤を開発する.
主な方法:
- サイクロフィリンA (CYPA) に結合する化合物を開発した.
- CYPAと活性RASとの間の新しいタンパク質インターフェースを設計した.
- 低内在反応性の共性阻害剤の反応速度を高めるためにこのインターフェースを使用した.
主要な成果:
- RASG12Dの共性修正のための選択的,酵素のような速度増強を達成しました.
- 臨床前モデルで有意な抗腫瘍活性を示す口服生物利用可能な化合物を開発した.
- 現在臨床試験中の有望な試験薬として,ゾルドンラシブ (RMC-9805) を特定した.
結論:
- CYPA-RASのバインディング戦略は,KRASG12Dをターゲットにすることの限界を効果的に克服しています.
- このアプローチは,KRASG12Dが誘発するがんに対する強力で選択的な共性阻害剤を生成します.
- この発見は,がんの変異に挑むための新しい治療法の臨床開発をサポートします.
関連する概念動画
02:38The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
01:24Small GTPases - Ras and Rho
4.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.2K
01:07MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K